SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in

Clinician reference, evidence review

Retatrutide

Investigational triple agonist

Triple GIP, GLP-1, and glucagon receptor agonist, investigational, not FDA approved

Reviewed by: Sabrina Runbeck, PA-C, MHS, MPH, Co-Founder, Scriptura Health. Physician assistant, public health master's, health sciences master's. Sabrina reviews the clinical layer of Scriptura Health, and she reviews every compound reference on this site.

Published: 2026-07-08. This page is an evidence review, not clinical instruction, and does not recommend dosing, cadence, routes, or prescribing decisions. Prescribing is the responsibility of a licensed clinician evaluating a specific patient.

Regulatory posture

Retatrutide is an investigational drug that is not FDA approved and remains in clinical development, with Phase 3 studies ongoing as of 2026. Because it has no marketing authorization and is an investigational new drug, it is not eligible for routine 503A or 503B compounding. It is not a controlled substance under the DEA.

Mechanism, plain English

Retatrutide acts on three hormone receptors at once: GLP-1, GIP, and glucagon. The GLP-1 and GIP actions help control blood sugar and appetite, while adding glucagon activity is thought to increase how many calories the body burns. The goal of hitting all three targets is greater weight loss and metabolic benefit, but this is still being tested.

Evidence landscape

Retatrutide is still investigational, and its evidence base is limited to earlier phase trials with Phase 3 results not yet fully reported. A Phase 2 randomized controlled trial reported large weight loss in adults with obesity, with effects that appeared greater than earlier single or dual agonists in similar populations. A separate Phase 2a randomized trial reported reductions in liver fat in people with metabolic dysfunction-associated steatotic liver disease. A review of the investigational agent summarizes its triple agonist rationale and early results while emphasizing that long-term efficacy and safety are not yet established. Conclusions about durable safety and outcomes await completion of the larger Phase 3 program.

Primary PubMed citations

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial , Jastreboff AM et al, New England Journal of Medicine, 2023. PMID: 37366315
  2. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial , Sanyal AJ et al, Nature Medicine, 2024. PMID: 38858523
  3. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity , Kaur M et al, European Journal of Clinical Pharmacology, 2024. PMID: 38367045

Citations selected from the PubMed literature. Every URL was checked at publication time. Scriptura's daily PubMed scan surfaces new studies for each compound as they index. See the regulatory and literature layers on the demo.

Scope of this page

This is a plain English summary of the peer reviewed literature and current regulatory posture. It is not a substitute for a licensed clinician's judgment on a specific patient. It does not recommend dosing, cadence, or route. Where the literature is limited or preclinical, this page says so, so a prescriber can weigh marketing claims against what the trials actually show.

More clinician references

  • BPC-157 , Cytoprotective peptide, research grade, not FDA approved
  • TB-500 , Regenerative peptide, research grade, not FDA approved
  • Semaglutide , GLP-1 receptor agonist, FDA approved
  • Tirzepatide , Dual GIP and GLP-1 receptor agonist, FDA approved
  • CJC-1295 , Growth hormone releasing hormone analog, research grade, not FDA approved
  • Ipamorelin , Growth hormone secretagogue, research grade, not FDA approved
  • Sermorelin , Growth hormone releasing hormone analog, research grade, not currently FDA marketed
  • Tesamorelin , Growth hormone releasing hormone analog, FDA approved
  • Thymosin Alpha-1 , Immunomodulatory peptide, not FDA approved in the US, orphan drug status

Want the evidence layer for your practice.

A daily one page regulatory brief and a plain English PubMed literature delta, in your Drive every morning. No prescribing, no dispensing, no pharmacy routing. Just the evidence and regulatory read a prescriber wants before writing the next protocol.

Book a demoRequest access
Retatrutide clinician reference: evidence review and regulatory posture | Scriptura Health | Scriptura Health